Aprea Therapeutics (APRE) announced the appointment of Nadeem Mirza, M.D., M.P.H. as Chief Medical Officer, CMO, of the Company, effective May 1, 2024. Dr. Mirza has been an integral part of the Company’s senior team as a consultant since February, 2023 and will now assume a more central role in leading the Company’s development of its expanding clinical pipeline. His prior experience includes serving as Senior Vice President, Clinical Development at Salarius Pharmaceuticals (SLRX), from 2020 to 2023
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE:
- Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
- Aprea Therapeutics files to sell 4.39M shares of common stock for holders
- Aprea Therapeutics price target raised to $11 from $9 at Wedbush
- Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Aprea Therapeutics sees cash runway into 3Q25